BioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded by Wall Street Zen to "Buy"

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a report issued on Saturday.

Several other equities research analysts also recently commented on the stock. Barclays lifted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Needham & Company LLC reiterated a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Royal Bank Of Canada reissued an "outperform" rating and issued a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Stock Performance

BCRX stock traded up $0.04 on Friday, hitting $9.00. 4,135,129 shares of the company's stock were exchanged, compared to its average volume of 3,029,036. The firm has a 50 day moving average price of $10.01 and a two-hundred day moving average price of $8.57. BioCryst Pharmaceuticals has a 12-month low of $6.02 and a 12-month high of $11.31. The stock has a market cap of $1.88 billion, a P/E ratio of -34.62, a price-to-earnings-growth ratio of 2.32 and a beta of 1.04.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its holdings in shares of BioCryst Pharmaceuticals by 1.8% during the fourth quarter. Rhumbline Advisers now owns 309,132 shares of the biotechnology company's stock worth $2,325,000 after buying an additional 5,615 shares in the last quarter. Ieq Capital LLC acquired a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $221,000. Los Angeles Capital Management LLC grew its stake in BioCryst Pharmaceuticals by 16.9% during the 4th quarter. Los Angeles Capital Management LLC now owns 101,188 shares of the biotechnology company's stock valued at $761,000 after acquiring an additional 14,655 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $192,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after purchasing an additional 91,998 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.